| 6MWD | 6-Minute Walking Distance |
| AE | Adverse Effects |
| AFT | Antifibrotic Therapy |
| ALAT | Asociación Latinoamericana De Tórax |
| ALT | Alanine Aminotransferase |
| AST | Aspartate Aminotransferase |
| ATS | American Thoracic Society |
| COPD | Chronic Pulmonary Obstructive Disease |
| CVD | Cardiovascular Diseases |
| CXR | Chest Radiography |
| DLCO | Diffusing Lung Capacity for Carbon Monoxide |
| ERS | European Respiratory Society |
| FVC | Forced Vital Capacity |
| GERD | Gastroesophageal Reflux Disease |
| GI | Gastrointestinal |
| HRTC | High-Resolution Computed Tomography |
| IHD | Ischemic Heart Disease |
| ILA | Interstitial Lung Abnormalities |
| ILD | Interstitial Lung Disease |
| IPF | Idiopathic Pulmonary Fibrosis |
| IQR | Interquartile Range |
| JRS | Japanese Respiratory Society |
| OSA | Obstructive Sleep Apnoea |
| PE | Pulmonary Embolism |
| PH | Pulmonary Hypertension |
| QoL | Quality of Life |
| RCT | Randomised Clinical Trial |
| RR | Risk Ratio |
| SBD | Sleep Breathing Disorder |
| SD | Standard Deviation |
| UIP | Usual Interstitial Pneumonia |
| FDA | Food and Drug Administration |
| VTE | Venous Thromboembolism |